Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor associated antigens in patients with newly diagnosed glioblastoma and then immunizing the patients with personalized DC-based cellular vaccine. In addition, allogeneic peripheral blood mononuclear cells (PBMCs) will be used as cellular vehicle for immunization. Safety and efficacy will be observed in the study.